AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial
Read More
Author: John Pinching
Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
Parsortix platform to support minimally invasive analysis across various cancer trials
Read More
Microbiotica reports positive results for MB097 in advanced melanoma
Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment
Read More
Prof Dr Wolfram Brugger
Asgard has appointed Prof Dr Wolfram Brugger as CMO
Read More
Kylie’s greatest hits
Building trust with patient organisations in the misinformation era
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
